Revenue from operations rose 16.6% YoY to Rs 1,815 crore in Q1FY25
The Pune-based drug maker which is reporting its maiden quarterly results following its successful listing on stock exchanges. The IPO was oversubscribed 67.86 times.
EBITDA rose 15.6% YoY to Rs 360 crore, while the EBITDA margins declined 20 basis points YoY to 19.8%.
The company’s domestic business, which accounts for 50% of overall revenues, grew by 14% to Rs 909 crore., led by steady base business performance and aided by distribution partnership for Sanofi’s cardiovascular brands. The Sanofi brand portfolio and team are now fully integrated into Emcure’s chronic team.On the international front, Europe saw a steady growth of 8.6%, led by an increase in the market share of the company’s base business. In Canada, Emcure’s subsidiaries Marcan and Mantra are witnessing strong traction and robust growth. Emcure is one of the top 10 generic players in the Canadian market. In Rest of World (RoW) markets, the company continues to see traction in its key focus markets.“We are experiencing the benefits of our investments in both domestic and international business,” said Satish Mehta, CEO and managing director, Emcure.”Going ahead, our focus will be on growing our India business and accelerating our product launches in international markets to drive strong growth,” Mehta said.
